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Cachexia is a complex metabolic syndrome associated with underlying illness, characterized by loss of muscle with or without loss of fat mass, and clinically diagnosed by the criteria including existence of underlying chronic disease, significant weight loss, and several evidences of abnormal metabolism.[1](#jcsm12117-bib-0001){ref-type="ref"} Because of the increasing prevalence of chronic diseases associated with the development of cachexia in advancing age, there is a large number of cachexia‐related hospitalizations with increasing costs in Western countries.[2](#jcsm12117-bib-0002){ref-type="ref"} Although most clinical data on cachexia have been reported from Western countries, cachexia may be a growing problem because of the larger population in Asia as well.[3](#jcsm12117-bib-0003){ref-type="ref"}

As the definition of cachexia includes body weight, we have to pay attention to the fact that the body size in Asian people is different from that in Western countries because of difference in diet, lifestyle, and metabolism.[4](#jcsm12117-bib-0004){ref-type="ref"} For example, the cutoff value of the body mass index (BMI) for the definition of obesity is smaller in Japan than in Western countries (≥25 kg/m^2^ in Japan[5](#jcsm12117-bib-0005){ref-type="ref"} and ≥30 kg/m^2^ in Western countries). Hence, there is still some possibility that not only the prevalence but also the ideal therapeutic strategies are different between in Asian people and Caucasians. Research results in Japan as an Asian aged country could become more important both for Asia and western countries.

The present state of cachexia in Japan {#jcsm12117-sec-0002}
======================================

Although the researchers in Asia have proposed an Asian definition for sarcopenia, which includes different cutoff values of muscle mass, muscle strength, and physical performance than that for Western countries,[6](#jcsm12117-bib-0006){ref-type="ref"}, [7](#jcsm12117-bib-0007){ref-type="ref"} there has been no distinct Asian definition for cachexia so far. A simple quotation from the global definition of cachexia[8](#jcsm12117-bib-0008){ref-type="ref"} has been included in the Clinical Guidelines for Infusion Therapy in Advanced Cancer Patients 2013 edited by the Japanese Society for Palliative Medicine, which is the only one cachexia definition with a cutoff for weight loss in Japan.[9](#jcsm12117-bib-0009){ref-type="ref"} No other definition of cachexia is shown in guidelines for chronic diseases such as heart failure, chronic obstructive pulmonary disease (COPD), or chronic kidney disease (CKD). Regarding heart failure, unintentional weight loss is alerted as cachexia in Guidelines for Treatment of Acute Heart Failure.[10](#jcsm12117-bib-0010){ref-type="ref"} For COPD patients, nutritional evaluation including weight assessment are recommended in a section of 'Nutrition management' in the guidelines for the diagnosis and treatment of COPD (3^rd^ edition) without referring to cachexia itself.[11](#jcsm12117-bib-0011){ref-type="ref"} In CKD guidelines, continual diet therapy is recommended without referring to cachexia itself.[12](#jcsm12117-bib-0012){ref-type="ref"} Lack of distinct cachexia definitions in Japan does not necessarily mean that researchers have accepted the global definition but may rather suggest that many researchers have not paid much attention to cachexia. In fact, there seems to be only one epidemiological research study reporting the prevalence of cachexia using weight loss as a part of the definition. Kimura *et al.* retrospectively reviewed the clinical data of consecutive patients with stage III or IV non‐small cell lung cancer who had received their first‐line chemotherapy, after having excluded those who were candidates for curative radiotherapy or who had received palliative radiotherapy.[13](#jcsm12117-bib-0013){ref-type="ref"} Cachexia, defined as a body weight loss \>5% over the past 6 month or \>2% in patients with a BMI \<20 kg/m^2^, was observed in 45.6% of the overall cohort, and its presence was associated with a poor prognosis. Although this number is within the range of Western countries (the prevalence ranging from 28 to 57% in advanced cancer[14](#jcsm12117-bib-0014){ref-type="ref"} and 50--80% in several types of cancer[15](#jcsm12117-bib-0015){ref-type="ref"}), we cannot compare the prevalence of cachexia in other types of cancer, heart failure, COPD, and CKD between Japan and Western countries. Hence, here we listed epidemiologic researches 'suggesting' the prevalence of cachexia, which includes BMI data in chronic diseases (Table [1](#jcsm12117-tbl-0001){ref-type="table-wrap"}). In recent years, a significant amount of data has been updated. However, many of these reports[16](#jcsm12117-bib-0016){ref-type="ref"}, [17](#jcsm12117-bib-0017){ref-type="ref"}, [18](#jcsm12117-bib-0018){ref-type="ref"}, [19](#jcsm12117-bib-0019){ref-type="ref"}, [20](#jcsm12117-bib-0020){ref-type="ref"}, [21](#jcsm12117-bib-0021){ref-type="ref"} had criteria including only BMI cut‐off of 18.5 kg/m^2^, which is related to the World Health Organization definition of 'malnutrition'.[22](#jcsm12117-bib-0022){ref-type="ref"} Table [1](#jcsm12117-tbl-0001){ref-type="table-wrap"} includes the data with tertile or quantile value of BMI, if the value is close to 20 kg/m^2^, which is one of the criteria in universal cachexia definition.[1](#jcsm12117-bib-0001){ref-type="ref"} The lack of data with regards to weight loss in most of the listed reports may be because of the fact that such data cannot be assembled from many databases in retrospect, if the researchers did not record the history of weight loss at the beginning of the studies. According to the epidemiologic data with BMI, one‐thirds of Japanese heart failure patients had a BMI \<20.3 kg/m^2^ [23](#jcsm12117-bib-0023){ref-type="ref"} whereas the prevalence of underweight (BMI \<20.7 kg/m^2^) was 13.6% in reports from Western countries.[24](#jcsm12117-bib-0024){ref-type="ref"} These data may suggest that there are more cachectic heart failure patients in Japan than in Western countries, or that the use of the same definition as in Western countries can overestimate the prevalence of cachexia in Japan. Although direct comparisons between Japan and Western countries cannot be performed either in CKD and COPD, the reported lowest quartile value of BMI (19.6 kg/m^2^) in CKD[25](#jcsm12117-bib-0025){ref-type="ref"} may match the prevalence of Western countries (30--60%[14](#jcsm12117-bib-0014){ref-type="ref"}). In COPD, the rate of low BMI (\<20 kg/m^2^) and underweight (BMI \<18.5 kg/m^2^) patients were 41%[26](#jcsm12117-bib-0026){ref-type="ref"} and 31%,[21](#jcsm12117-bib-0021){ref-type="ref"} which seem to be high in comparison with the prevalence of cachexia in Western countries (27--35%).[14](#jcsm12117-bib-0014){ref-type="ref"}

###### 

Epidemiologic researches suggesting the prevalence of cachexia

  Disease                                   Inclusion criteria               Exclusion criteria                                                  Reference                                                             Definition used                                                                                      *N*      Prevalence (%)
  ----------------------------------------- -------------------------------- ------------------------------------------------------------------- --------------------------------------------------------------------- ------------------------ --------------------------------------------------------------------------- -------- ----------------
  Cancer                                    Advanced NSCLC planned to CT     Patients planned to radiotherapy                                    Kimura *et al*. 2015 [13](#jcsm12117-bib-0013){ref-type="ref"}        Cachexia                 Weight loss \>5% over 6 month or \>2% in patients with a BMI \<20 kg/m^2^   134      46
  Head and neck cancer                      None                             Takenaka *et al*. 2014 [16](#jcsm12117-bib-0016){ref-type="ref"}    Underweight                                                           BMI \<18.5 kg/m^2^       726                                                                         18       
  Breast cancer planned to CT and surgery   Distant metastasis               Iwase *et al*. 2014 [17](#jcsm12117-bib-0017){ref-type="ref"}       Underweight                                                           BMI \<18.5 kg/m^2^       248                                                                         7        
  Stomach cancer                            None                             Minami *et al*. 2015 [18](#jcsm12117-bib-0018){ref-type="ref"}      Underweight                                                           BMI \<18.5 kg/m^2^       1033                                                                        8        
  Chronic HF                                Stable HF                        None                                                                Nochioka *et al*. 2010 [19](#jcsm12117-bib-0019){ref-type="ref"}      Underweight              BMI \<18.5 kg/m^2^                                                          972      9
  Hospitalized HF                           Acute CVD, dialysis, cancer      Takiguchi *et al*. 2014 [20](#jcsm12117-bib-0020){ref-type="ref"}   Underweight                                                           BMI \<18.5 kg/m^2^       648                                                                         13       
  Hospitalized HF                           None                             Hamaguchi *et al*. 2010 [23](#jcsm12117-bib-0023){ref-type="ref"}   Lower tertile in BMI                                                  BMI \<20.3 kg/m^2^       2488                                                                        \(33\)   
  Hospitalized HF                           AMI, dialysis, cardiac surgery   Komukai *et al*. 2012 [42](#jcsm12117-bib-0042){ref-type="ref"}     Lowest quartile in BMI                                                BMI ≤21.4 kg/m^2^        219                                                                         \(25\)   
  CKD                                       Hemodialysis                     Acute CVD, active infection, cancer                                 Takahashi *et al*. 2012 [25](#jcsm12117-bib-0025){ref-type="ref"}     Lowest quartile in BMI   BMI \<19.6 kg/m^2^                                                          1228     \(25\)
  COPD                                      Stable COPD                      Tuberculosis, cancer                                                Higashimoto *et al*. 2011 [26](#jcsm12117-bib-0026){ref-type="ref"}   Low BMI                  BMI \<20 kg/m^2^                                                            69       41
  Hospitalized COPD (\>65 y)                None                             Yamauchi *et al*. 2014 [21](#jcsm12117-bib-0021){ref-type="ref"}    Underweight                                                           BMI \<18.5 kg/m^2^       263 940                                                                     31       

BMI, body mass index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CT, Chemotherapy; CVD, cardiovascular diseases; HF, heart failure; NSCLC, non‐small cell lung cancer.

Recent cachexia research in Japan {#jcsm12117-sec-0003}
=================================

As expected by the lack of epidemiologic data in cachexia, most of observational/interventional studies in Japan have been based on various definitions for cachexia. Table [2](#jcsm12117-tbl-0002){ref-type="table-wrap"} shows observational/interventional parallel‐group comparison studies using some clear definitions for cachexia. There are wide difference among studies in the definition of cachexia, although some of them have taken weight loss into account as part of the definition.[27](#jcsm12117-bib-0027){ref-type="ref"}, [28](#jcsm12117-bib-0028){ref-type="ref"}, [29](#jcsm12117-bib-0029){ref-type="ref"}, [30](#jcsm12117-bib-0030){ref-type="ref"}, [31](#jcsm12117-bib-0031){ref-type="ref"}, [32](#jcsm12117-bib-0032){ref-type="ref"}, [33](#jcsm12117-bib-0033){ref-type="ref"} Four interventional studies using ghrelin and octanoic acid‐rich formula have been reported in the field of COPD, including two studies with weight loss \>7.5% over 6 months[32](#jcsm12117-bib-0032){ref-type="ref"}, [33](#jcsm12117-bib-0033){ref-type="ref"} and 2 studies with BMI \<21 kg/m^2^ [34](#jcsm12117-bib-0034){ref-type="ref"}, [35](#jcsm12117-bib-0035){ref-type="ref"} as the definition of cachexia. On the other hand, there is no published interventional research targeting cachexia in cancer, heart failure, and CKD. Most of the studies in cancer and heart failure focused on blood levels of hormones or cytokines in those with and without cachexia, but used definitions for cachexia that are completely different from each other. Two of them did not include body weight, but only included cancer stage[36](#jcsm12117-bib-0036){ref-type="ref"} or blood markers[37](#jcsm12117-bib-0037){ref-type="ref"} as definitions of cachexia. The other studies in cancer had an endpoint of weight loss and inflammatory responses[38](#jcsm12117-bib-0038){ref-type="ref"}, [39](#jcsm12117-bib-0039){ref-type="ref"} without any definition of cachexia. The reasons for such a wide variety of inclusion criteria are not clear, but it could be speculated that the researchers intended to simplify the enrollment of patients.[40](#jcsm12117-bib-0040){ref-type="ref"} Although the number of clinical trials targeting cachexia is very limited in Japan so far, researchers may have a potential to produce more evidence in this field, having fruitful results as their background especially in the field of basic research.[41](#jcsm12117-bib-0041){ref-type="ref"} Further studies targeting cachexia patients defined by universal criteria are desirable when we consider to apply the results for Western countries.

###### 

Observational and interventional studies for cachexia and definitions

  Disease      Classification                                                      Reference                                                           Definition of cachexia                                                                         Study endpoints                                                             Type of study    *N*
  ------------ ------------------------------------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- ---------------- -----
  Cancer       Colorectal and gastric cancer                                       Shibata *et al*. 2002 [27](#jcsm12117-bib-0027){ref-type="ref"}     Recurrence or metastasis and \>5% weight loss over 3 months or alb \<3.0 g/dL                  The production of cytokines by peripheral blood mononuclear cells           Observational    61
               Lung cancer                                                         Shimizu *et al*. 2003 [28](#jcsm12117-bib-0028){ref-type="ref"}     Weight loss \>5% over 3 month                                                                  Plasma ghrelin levels                                                       Observational    43
               Gastric cancer                                                      Takahashi *et al*. 2009 [36](#jcsm12117-bib-0036){ref-type="ref"}   Stage IV, subjective symptoms                                                                  Plasma ghrelin and leptin levels                                            Observational    16
               Any cancers                                                         Naito *et al*. 2012 [37](#jcsm12117-bib-0037){ref-type="ref"}       GPS as a continuous scale                                                                      Oxycodone metabolism                                                        Observational    47
               Pancreatic cancer                                                   Fujiwara *et al*. 2014 [29](#jcsm12117-bib-0029){ref-type="ref"}    Performance Status \>0, anorexia, and weight loss \>10% over 6 months                          Serum metabolite levels                                                     Observational    21
               Any cancers                                                         Suno *et al*. 2015 [30](#jcsm12117-bib-0030){ref-type="ref"}        Weight loss \>5% over 6 month or \>2% in patients with a BMI \<20 kg/m^2^ or with sarcopenia   Dose‐adjusted plasma fentanyl concentrations                                Observational    21
  Chronic HF   Stable HF                                                           Nagaya *et al*. 2001 [31](#jcsm12117-bib-0031){ref-type="ref"}      Weight loss \>7.5% over 6 month                                                                Plasma levels of ghrelin and other cytokines                                Observational    74
  COPD         COPD                                                                Ashitani *et al*. 2009[32](#jcsm12117-bib-0032){ref-type="ref"}     Weight loss \>7.5% over 6 month or BMI \<21 kg/m^2^                                            The effect of an octanoic acid‐rich formula on plasma acyl‐ghrelin levels   Interventional   23
  COPD         Nagaya *et al*. 2005 [33](#jcsm12117-bib-0033){ref-type="ref"}      Weight loss \>7.5% over 6 month                                     The effects of ghrelin on body composition, muscle strength, and functional capacity           Interventional                                                              7                
  COPD         Miki *et al*. 2012 [34](#jcsm12117-bib-0034){ref-type="ref"}        BMI \<21 kg/m^2^                                                    The efficacy and safety of adding ghelin to pulmonary rehabilitation                           Interventional                                                              33               
  COPD         Matsumoto *et al*. 2015 [35](#jcsm12117-bib-0035){ref-type="ref"}   BMI \<21 kg/m^2^                                                    The optimal dose of ghrelin                                                                    Interventional                                                              44               

BMI, body mass index; COPD, chronic obstructive pulmonary diseases; GPS, the glasgow Prognostic Score; calculated using serum albumin and C reacting protein, HF; heart failure.

Conclusions {#jcsm12117-sec-0004}
===========

In recent years, many epidemiological data have been updated reporting the distribution of BMI in chronic diseases in Japan, however, most of them have not referred to the definition of cachexia. The clinical course and background of cachectic patients in Japan may be different from that of patients in Western countries. There have been several observational studies comparing patients with and without cachexia, but the definitions of cachexia used have widely varied among studies. Interventional clinical trials for cachectic patients are still lacking especially in cancer, heart failure, and CKD. Further studies are needed to assess the epidemiologic/pathological background, as well as the effect of therapeutic approach, in cachexia.
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